Payment overview · 2025
General Payments
$396.67
20 reported records · 12 companies
Healthcare provider profile · identity verified
Jared Christopher Basham, MD
Allopathic & Osteopathic Physicians|Family Medicine · INDIANAPOLIS, IN · NPI 1316907009
Verified facts
What the public records show
CMS Open Payments records show Jared Christopher Basham, MD received $396.67 in general payments during 2025 across 20 reported records.
Lilly USA, LLC accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $106.21 | 26.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.50 | 22.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $43.91 | 11.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.95 | 6.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.80 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.68 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.74 | 4.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.71 | 4.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.42 | 3.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.41 | 3.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.72 | 3.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $10.62 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $396.67 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $74.46 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.53 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $43.91 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.75 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.97 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $10.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
54 | 54 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 140 |
| Lisinopril | Lisinopril | 405 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 336 | 81 |
| Omeprazole | Omeprazole | 317 | 82 |
| Simvastatin | Simvastatin | 260 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 45 |
| Losartan Potassium | Losartan Potassium | 240 | 65 |
| Montelukast Sodium | Montelukast Sodium | 225 | 57 |
| Gabapentin | Gabapentin | 221 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 32 |
| Trazodone Hcl | Trazodone Hcl | 148 | 41 |
| Metformin Hcl | Metformin Hcl | 147 | 40 |
| Alprazolam | Alprazolam | 145 | 29 |
| Tramadol Hcl | Tramadol Hcl | 128 | 21 |
| Famotidine | Famotidine | 124 | 36 |
| Mounjaro | Tirzepatide | 116 | 17 |
| Allopurinol | Allopurinol | 109 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 48 |
| Metformin Hcl Er | Metformin Hcl | 103 | 29 |
| Sertraline Hcl | Sertraline Hcl | 100 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 27 |
| Ezetimibe | Ezetimibe | 95 | 30 |
| Ozempic | Semaglutide | 91 | 16 |
| Carvedilol | Carvedilol | 89 | 24 |
| Furosemide | Furosemide | 81 | 19 |
| Glipizide Er | Glipizide | 80 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 22 |
| Jardiance | Empagliflozin | 69 | 18 |
| Mirtazapine | Mirtazapine | 67 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 25 |
| Atenolol | Atenolol | 63 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Pregabalin | Pregabalin | 61 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 16 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 54 | 54 |
| Bupropion Xl | Bupropion Hcl | 54 | 15 |
| Celecoxib | Celecoxib | 51 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 51 | 38 |
| Synthroid | Levothyroxine Sodium | 50 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 14 |
| Alendronate Sodium | Alendronate Sodium | 46 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 12 |
| Clonazepam | Clonazepam | 45 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 45 | suppressed |
| Eliquis | Apixaban | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 11 |
| Benazepril Hcl | Benazepril Hcl | 43 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 17 |
| Meloxicam | Meloxicam | 43 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | 11 |
| Valsartan | Valsartan | 42 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | 12 |
| Finasteride | Finasteride | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | suppressed |
| Lovastatin | Lovastatin | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 29 | suppressed |
| Prednisone | Prednisone | 27 | 22 |
| Carisoprodol | Carisoprodol | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Primidone | Primidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Niacin Er | Niacin | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Dexamethasone | Dexamethasone | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 12 | 12 |
| Azithromycin | Azithromycin | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tdvax | Tetanus, Diphtheria Tox,adult | 11 | 11 |
| Tenivac | Tetanus-Diphtheria Toxoids/Pf | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $396.67 · 20 records | Lilly USA, LLC | BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FANAPT, GARDASIL 9, Heplisav-B, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error